Department of Hematology, Istanbul Kartal Dr Lutfi Kurdar City Hospital, Istanbul, Turkey.
J Oncol Pharm Pract. 2023 Oct;29(7):1652-1660. doi: 10.1177/10781552221132554. Epub 2022 Oct 13.
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma is an undesirable and sometimes severe side effect. Our study aimed to examine whether there was a difference in bortezomib-induced peripheral neuropathy between multiple myeloma patients with normal and abnormal genetic characteristics.
This retrospective analysis is based on the assessment of bortezomib-induced peripheral neuropathy frequency in newly-diagnosed multiple myeloma patients with normal ( = 68) and abnormal ( = 45) genetic profiles. A total of 113 patients diagnosed with multiple myeloma according to the International Myeloma Working Group criteria, between 2016 and 2021, were included in this study.
Neuropathy was detected in 42 (37.1%) patients. The most common genetic anomalies were 13q del (in 28.9%), (4.14) (in 22.2%), and trisomy 7 (in 20.0%). When patients with and without bortezomib-induced peripheral neuropathy were compared, the only significant differences were observed for age ( = 0.032) and genetic grouping ( = 0.001); whereas other characteristics that could be associated with bortezomib-induced peripheral neuropathy were similarly distributed in both groups. Bortezomib-induced peripheral neuropathy was significantly more frequent in multiple myeloma patients with normal genetic characteristics ( = 0.001).
As a result of our study, it was observed that the frequency of bortezomib neuropathy was significantly higher in patients with normal genetic features compared to those with abnormal genetic features. This result suggested that factors other than genetic factors should be investigated to clarify the etiology of bortezomib-associated neuropathy in patients with multiple myeloma.
硼替佐米诱导的多发性骨髓瘤患者周围神经病是一种不理想的、有时甚至是严重的副作用。本研究旨在探讨多发性骨髓瘤患者的遗传特征正常和异常时，硼替佐米诱导的周围神经病是否存在差异。
本回顾性分析基于对新诊断的多发性骨髓瘤患者（正常组 = 68 例，异常组 = 45 例）硼替佐米诱导的周围神经病频率的评估。本研究共纳入了 2016 年至 2021 年间根据国际骨髓瘤工作组标准诊断为多发性骨髓瘤的 113 例患者。
42 例（37.1%）患者检测到神经病变。最常见的遗传异常是 13q 缺失（28.9%）、（4.14）（22.2%）和 7 号染色体三体（20.0%）。当比较有和没有硼替佐米诱导的周围神经病的患者时，只有年龄（ = 0.032）和遗传分组（ = 0.001）存在显著差异；而其他可能与硼替佐米诱导的周围神经病相关的特征在两组中分布相似。多发性骨髓瘤患者的遗传特征正常时，硼替佐米诱导的周围神经病明显更常见（ = 0.001）。
由于本研究的结果，观察到在遗传特征正常的多发性骨髓瘤患者中，硼替佐米神经病的频率明显高于遗传特征异常的患者。这一结果表明，除了遗传因素外，还应调查其他因素，以阐明多发性骨髓瘤患者硼替佐米相关周围神经病的病因。
